ClinicalTrials.gg
CompletedNCT00352053Updated Jul 14, 2015Results posted

Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy

A Phase 3 interventional study of Tenofovir DF and Placebo in HIV Infections, sponsored by Gilead Sciences. Completed at 18 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-07-14.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.

Enrollment
51st of 94
87 · median 99
Started
2006
with 7 others
Phase 3
16 of 98
none open now
Registered
43rd of 98
by date
Lead sponsor
17 of 98
Gilead Sciences

Among the 98 studies testing tenofovir in HIV Infections, this one is the 51st largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2006, is one of 16 in phase 3, and was the 43rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing tenofovir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) plus a genotype-guided optimized background regimen (OBR) compared to placebo plus OBR in the treatment of human immunodeficiency virus type 1 (HIV-1) infected antiretroviral treatment-experienced adolescents with plasma HIV-1 ribonucleic acid (RNA) levels greater than or equal to 1000 copies/mL.

Read the detailed description

This is a 48-week, randomized, double-blind, placebo-controlled, multicenter study of the safety and efficacy of tenofovir DF as part of an optimized antiretroviral regimen in HIV-1 infected adolescents (12 years to \< 18 years of age) who are failing their current antiretroviral regimen and have HIV-1 RNA levels ≥ 1000 copies/mL at screening. Data from three consecutive 96-week study extensions have been used to evaluate the long-term efficacy, safety, and tolerability of open-label tenofovir DF as part of an antiviral regimen, providing data for up to 336 weeks of total drug exposure.

Pretreatment:

HIV-1 genotyping will be performed as part of the screening assessments to assist in the construction of an OBR, defined as at least 3, but no more than 5 antiretroviral agents, not including tenofovir DF or placebo.

Randomized Phase:

Participants will be randomized in a 1:1 ratio to receive either tenofovir DF + OBR, or placebo + OBR. The majority of efficacy and safety assessments will be performed at each clinic visit (Weeks 4, 8, 16, 24, 32, 40, and 48). At Week 24, participants who are adherent to study drug (in the opinion of the investigator), but do not demonstrate a ≥ 0.5 log10 copies/mL decrease from baseline in HIV-1 RNA, will be considered to be nonresponders and will be unblinded. Nonresponders randomized to the placebo group will be given the option to continue on study and receive open-label tenofovir DF with an appropriate background regimen determined by the investigator. Nonresponders randomized to the tenofovir DF treatment group will be discontinued from the study.

Extension Phases:

After completing 48 weeks of double-blind treatment with tenofovir DF or placebo, participants who have not reached 18 years of age, and who, in the opinion of the investigator, would derive clinical benefit from the use of open-label tenofovir DF, will be given the option to continue (or initiate) treatment with open-label tenofovir DF in the first of three 96 week study extension periods. Nonresponders who receive open-label tenofovir DF after Week 24 will also be considered eligible for the first study extension if they met the above criteria at Week 48.

After completing the first 96 week study extension, participants who have not reached 18 years of age, and who have shown ongoing clinical benefit from tenofovir DF, will be given the option to continue receiving open-label tenofovir DF for an additional 96 weeks or until tenofovir DF became commercially available in the country where the participants are enrolled, whichever occurs first.

After completing the second 96 week study extension, participants who have not reached 18 years of age, and who have shown ongoing clinical benefit from tenofovir DF, will be given the option to continue receiving open-label tenofovir DF for an additional 96 weeks or until tenofovir DF became commercially available in the country where the participants are enrolled, whichever occurs first.

Presentation of data:

After the randomized phase of the study, participants randomized to placebo during the randomized phase of the study and then switch to open-label tenofovir DF will have their baseline reset (defined as open-label baseline), and only outcome data collected after (on/after for adverse events (AEs)/concomitant medications) participants receive their first dose of open-label tenofovir DF will be included.

03

Conditions studied

  • HIV Infections

Keywords

  • Phase 3
  • Randomized, Double-Blind
  • Control
  • Treatment-Experienced
  • OBR
  • Optimized background regimen
  • Highly Active Antiretroviral Therapy
  • HAART
  • HIV
  • HIV-1
  • AIDS Virus
  • Human Immunodeficiency Virus
  • Acquired Immune Deficiency Syndrome Virus
  • Virus
  • Human Immunodeficiency
  • Pediatrics
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Weight ≥ 35 kg
  • Documented laboratory diagnosis of infection
  • Plasma HIV-1 RNA ≥ 1000 copies/mL
  • Prior antiretroviral treatment experience with at least 2 antiretroviral drug classes
  • Naive to tenofovir DF
  • Absence of K65R mutation on genotypic testing

Exclusion Criteria:

  • Patients requiring didanosine in background regimen
  • Prior history of significant renal disease
  • Prior history of significant bone disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    OBR + Tenofovir DF

    Tenofovir DF administered orally, one tablet daily without regard to meals

    Drug: Tenofovir DF

  • Placebo comparator
    OBR + Tenofovir DF Placebo

    Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals

    Drug: Placebo

Interventions

  • Tenofovir DF 300-mg tablet, administered orally, daily + OBR

  • DrugPlacebo

    Tenofovir DF Placebo administered orally, daily + OBR

06

What researchers measure

Primary outcomes

  1. Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA

    DAVG24 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 24 minus the baseline value. DAVG24 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value. Data for participants who discontinued the randomized (double-blind) phase of the study early were included up until the point of study discontinuation (missing data not imputed).

    Time frame: Baseline to 24 Weeks

Secondary outcomes

  1. Time-weighted Average Change From Baseline Through Week 48 (DAVG48) in Plasma HIV-1 RNA

    DAVG48 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 48 minus the baseline value. DAVG48 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value. Data for participants who discontinued the double-blind phase of the study early were included up until the point of discontinuation from the study (ie, missing data were not imputed).

    Time frame: Baseline to 48 weeks

  2. Change From Baseline to Week 24 in HIV-1 RNA

    Time frame: Baseline to 24 weeks

  3. Change From Baseline to Week 48 in HIV-1 RNA

    Time frame: Baseline to 48 weeks

  4. Change From Baseline to Week 96 in HIV-1 RNA

    Time frame: Baseline to 96 weeks

  5. Change From Baseline to Week 144 in HIV-1 RNA

    Time frame: Baseline to 144 weeks

  6. Change From Baseline to Week 192 in HIV-1 RNA

    Time frame: Baseline to 192 weeks

  7. Change From Baseline to Week 240 in HIV-1 RNA

    Time frame: Baseline to 240 weeks

  8. Change From Baseline to Week 288 in HIV-1 RNA

    Time frame: Baseline to 288 weeks

  9. Change From Baseline to Week 336 in HIV-1 RNA

    No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

    Time frame: Baseline to 336 weeks

  10. Change From Baseline to Week 24 in Cluster Determinant 4 (CD4) Count

    Time frame: Baseline to 24 weeks

  11. Change From Baseline to Week 48 in CD4 Count

    Time frame: Baseline to 48 weeks

  12. Change From Baseline to Week 96 in CD4 Count

    Time frame: Baseline to 96 weeks

  13. Change From Baseline to Week 144 in CD4 Count

    Time frame: Baseline to 144 weeks

  14. Change From Baseline to Week 192 in CD4 Count

    Time frame: Baseline to 192 weeks

  15. Change From Baseline to Week 240 in CD4 Count

    Time frame: Baseline to 240 weeks

  16. Change From Baseline to Week 288 in CD4 Count

    Time frame: Baseline to 288 weeks

  17. Change From Baseline to Week 336 in CD4 Count

    No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

    Time frame: Baseline to 336 weeks

  18. Change From Baseline to Week 24 in CD4 Percentage

    CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

    Time frame: Baseline to 24 weeks

  19. Change From Baseline to Week 48 in CD4 Percentage

    CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

    Time frame: Baseline to 48 weeks

  20. Change From Baseline to Week 96 in CD4 Percentage

    CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

    Time frame: Baseline to 96 weeks

  21. Change From Baseline to Week 144 in CD4 Percentage

    CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

    Time frame: Baseline to 144 weeks

  22. Change From Baseline to Week 192 in CD4 Percentage

    CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

    Time frame: Baseline to 192 weeks

  23. Change From Baseline to Week 240 in CD4 Percentage

    CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

    Time frame: Baseline to 240 weeks

  24. Change From Baseline to Week 288 in CD4 Percentage

    CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

    Time frame: Baseline to 288 weeks

  25. Change From Baseline to Week 336 in CD4 Percentage

    No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

    Time frame: Baseline to 336 weeks

  26. Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 24

    Time frame: Baseline to 24 weeks

  27. Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 48

    Time frame: Baseline to 48 weeks

  28. Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 96

    Time frame: Baseline to 96 weeks

  29. Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 144

    Time frame: Baseline to 144 weeks

  30. Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 192

    Time frame: Baseline to 192 weeks

  31. Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 240

    Time frame: Baseline to 240 weeks

  32. Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0log 10 Copies/mL From Baseline to Week 288

    Time frame: Baseline to 288 weeks

  33. Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 336

    No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

    Time frame: Baseline to 336 weeks

  34. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 24

    Time frame: Week 24

  35. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48

    Time frame: Week 48

  36. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96

    Time frame: Week 96

  37. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144

    Time frame: Week 144

  38. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 192

    Time frame: Week 192

  39. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 240

    Time frame: Week 240

  40. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 288

    Time frame: Week 288

  41. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 336

    No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

    Time frame: Week 336

  42. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24

    Time frame: Week 24

  43. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

    Time frame: Week 48

  44. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

    Time frame: Week 96

  45. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144

    Time frame: Week 144

  46. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 192

    Time frame: Week 192

  47. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 240

    Time frame: Week 240

  48. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 288

    Time frame: Week 288

  49. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 336

    No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

    Time frame: Week 336

  50. Percentage of Participants With Virologic Failure Through Week 48

    Virologic failure was defined as either nonresponse or viral rebound. * Nonresponse (failure to achieve response). Response was defined as either * A ≥ 0.5 log10 copies/mL decrease in HIV-1 RNA from baseline at 2 consecutive visits, or * HIV-1 RNA \< 400 copies/mL at 2 consecutive visits. * Viral rebound was defined as either * Participants who achieved a ≥ 0.5 log10 copies/mL decrease from baseline in plasma HIV-1 RNA at 2 consecutive visits, who then subsequently achieved plasma HIV-1 RNA values ≥ 1.0 log10 copies/mL above their on-study nadir (lowest value) and/or plasma HIV-1 RNA values ≥ the baseline value at 2 consecutive visits, or * Participants who achieved plasma HIV-1 RNA levels of \< 400 copies/mL at 2 consecutive visits, and then subsequently had plasma HIV-1 RNA levels \> 1000 copies/mL at 2 consecutive visits. The virologic failure rate was estimated from Kaplan-Meier product limit method by including all HIV-1 RNA data collected during the double-blind phase.

    Time frame: Up to 48 weeks

07

Results

Posted Aug 19, 2010
Limitations and caveats
Participants left the study for a number of reasons (eg, turned 18 years old, switched to a different HIV treatment regimen), which led to small numbers of participants analyzed at later time points, and the study was concluded earlier than planned.

Participant flow

There were 17 sites in Brazil and 1 site in Panama. First participant was screened on 13 June 2006. The last study visit occurred on 19 December 2013.

Double-Blind Phase (Through Week 48)
Participant flow — Double-Blind Phase (Through Week 48)
MilestoneTenofovir DFPlacebo
Started4542
Completed2729
Not completed1813
Withdrew: Virologic failure1410
Withdrew: Physician decision22
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01
Withdrew: Intolerance to antiretroviral regimen10
First Extension Phase (Weeks 48-144)
Participant flow — First Extension Phase (Weeks 48-144)
MilestoneTenofovir DFPlacebo
Started2436
Completed1219
Not completed1217
Withdrew: Physician decision913
Withdrew: Lack of efficacy14
Withdrew: Pregnancy10
Withdrew: Lost to follow-up10
Second Extension Phase (Weeks 144-240)
Participant flow — Second Extension Phase (Weeks 144-240)
MilestoneTenofovir DFPlacebo
Started914
Completed49
Not completed55
Withdrew: Physician decision44
Withdrew: Withdrawal by subject11
Third Extension Phase (Weeks 240-294)
Participant flow — Third Extension Phase (Weeks 240-294)
MilestoneTenofovir DFPlacebo
Started14
Completed02
Not completed12
Withdrew: Lack of efficacy11
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryTime-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA

DAVG24 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 24 minus the baseline value. DAVG24 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value. Data for participants who discontinued the randomized (double-blind) phase of the study early were included up until the point of study discontinuation (missing data not imputed).

Time frame:
Baseline to 24 Weeks
Reported as:
Median · log10 copies/mL
Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA
log10 copies/mLTenofovir DFPlacebo
Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA-1.580 (-2.15 to -0.27)-1.549 (-2.36 to -0.34)
Statistical analysis
  • Tenofovir DF vs Placebo · Van Elteren test · p = 0.55 (No adjustments for multiple comparisons were made.)P-value is from a Van Elteren test stratified by baseline genotypic sensitivity score (GSS) (without tenofovir DF) \<= or \> median (median GSS is 2).
SecondaryTime-weighted Average Change From Baseline Through Week 48 (DAVG48) in Plasma HIV-1 RNA

DAVG48 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 48 minus the baseline value. DAVG48 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value. Data for participants who discontinued the double-blind phase of the study early were included up until the point of discontinuation from the study (ie, missing data were not imputed).

Time frame:
Baseline to 48 weeks
Reported as:
Median · log10 copies/mL
Time-weighted Average Change From Baseline Through Week 48 (DAVG48) in Plasma HIV-1 RNA
log10 copies/mLTenofovir DFPlacebo
Time-weighted Average Change From Baseline Through Week 48 (DAVG48) in Plasma HIV-1 RNA-1.423 (-2.25 to -0.25)-1.352 (-2.72 to -0.53)
Statistical analysis
  • Tenofovir DF vs Placebo · Van Elteren test · p = 0.40 (No adjustments for multiple comparisons were made.)P-value is from a Van Elteren test stratified by baseline GSS (without tenofovir DF) \<= or \> median (median GSS is 2).
SecondaryChange From Baseline to Week 24 in HIV-1 RNA
Time frame:
Baseline to 24 weeks
Reported as:
Median · log10 copies/mL
Change From Baseline to Week 24 in HIV-1 RNA
log10 copies/mLTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 24 in HIV-1 RNA-1.23 (-2.3 to -0.1)-1.27 (-2.8 to -0.1)0.0 (0.0 to 0.0)-0.1 (-0.6 to 0.3)
Statistical analysis
  • Tenofovir DF vs Placebo · Van Elteren test · p = 0.58 (No adjustments for multiple comparisons were made.)P-value is from a Van Elteren test stratified by baseline GSS (without tenofovir DF) \<= or \> median (median GSS is 2).
SecondaryChange From Baseline to Week 48 in HIV-1 RNA
Time frame:
Baseline to 48 weeks
Reported as:
Median · log10 copies/mL
Change From Baseline to Week 48 in HIV-1 RNA
log10 copies/mLTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 48 in HIV-1 RNA-0.97 (-2.3 to 0.0)-1.53 (-3.0 to 0.0)0.0 (0.0 to 0.6)0.2 (-0.1 to 0.5)
Statistical analysis
  • Tenofovir DF vs Placebo · Van Elteren test · p = 0.37 (No adjustments for multiple comparisons were made.)P-value is from a Van Elteren test stratified by baseline GSS (without tenofovir DF) \<= or \> median (median GSS is 2).
SecondaryChange From Baseline to Week 96 in HIV-1 RNA
Time frame:
Baseline to 96 weeks
Reported as:
Median · log10 copies/mL
Change From Baseline to Week 96 in HIV-1 RNA
log10 copies/mLTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 96 in HIV-1 RNA-2.1 (-2.5 to -0.6)0.0 (0.0 to 0.9)0.1 (-1.4 to 0.8)
SecondaryChange From Baseline to Week 144 in HIV-1 RNA
Time frame:
Baseline to 144 weeks
Reported as:
Median · log10 copies/mL
Change From Baseline to Week 144 in HIV-1 RNA
log10 copies/mLTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 144 in HIV-1 RNA-2.5 (-2.7 to -2.2)0.2 (0.0 to 1.6)0.7 (0.6 to 0.8)
SecondaryChange From Baseline to Week 192 in HIV-1 RNA
Time frame:
Baseline to 192 weeks
Reported as:
Median · log10 copies/mL
Change From Baseline to Week 192 in HIV-1 RNA
log10 copies/mLTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 192 in HIV-1 RNA-2.0 (-2.5 to -0.7)0.0 (0.0 to 0.2)-0.1 (-1.4 to 1.3)
SecondaryChange From Baseline to Week 240 in HIV-1 RNA
Time frame:
Baseline to 240 weeks
Reported as:
Median · log10 copies/mL
Change From Baseline to Week 240 in HIV-1 RNA
log10 copies/mLTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 240 in HIV-1 RNA-2.5 (-2.6 to -2.2)-0.4 (-0.8 to 0.0)-1.4 (-1.4 to -1.4)
SecondaryChange From Baseline to Week 288 in HIV-1 RNA
Time frame:
Baseline to 288 weeks
Reported as:
Median · log10 copies/mL
Change From Baseline to Week 288 in HIV-1 RNA
log10 copies/mLTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 288 in HIV-1 RNA-1.1 (-1.1 to -1.1)-0.8 (-0.8 to -0.8)0.6 (0.6 to 0.6)
SecondaryChange From Baseline to Week 336 in HIV-1 RNA

No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

Time frame:
Baseline to 336 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 24 in Cluster Determinant 4 (CD4) Count
Time frame:
Baseline to 24 weeks
Reported as:
Median · cells/mm3
Change From Baseline to Week 24 in Cluster Determinant 4 (CD4) Count
cells/mm3Tenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 24 in Cluster Determinant 4 (CD4) Count69 (-26 to 172)49 (-3 to 156)-43 (-181 to 53)-12 (-48 to 59)
Statistical analysis
  • Tenofovir DF vs Placebo · Van Elteren test · p = 0.71 (No adjustments for multiple comparisons were made.)P-value is from a Van Elteren test stratified by baseline GSS (without tenofovir DF) \<= or \> median (median GSS is 2).
SecondaryChange From Baseline to Week 48 in CD4 Count
Time frame:
Baseline to 48 weeks
Reported as:
Median · cells/mm3
Change From Baseline to Week 48 in CD4 Count
cells/mm3Tenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 48 in CD4 Count152 (-4 to 241)148 (42 to 289)15 (-69 to 95)-47 (-83 to 67)
Statistical analysis
  • Tenofovir DF vs Placebo · Van Elteren test · p = 0.47 (No adjustments for multiple comparisons were made.)P-value is from a Van Elteren test stratified by baseline GSS (without tenofovir DF) \<= or \> median (median GSS is 2).
SecondaryChange From Baseline to Week 96 in CD4 Count
Time frame:
Baseline to 96 weeks
Reported as:
Median · cells/mm3
Change From Baseline to Week 96 in CD4 Count
cells/mm3Tenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 96 in CD4 Count152 (52 to 266)-6 (-96 to 85)-69 (-75 to 278)
SecondaryChange From Baseline to Week 144 in CD4 Count
Time frame:
Baseline to 144 weeks
Reported as:
Median · cells/mm^3
Change From Baseline to Week 144 in CD4 Count
cells/mm^3Tenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 144 in CD4 Count188 (53 to 361)-88 (-165 to 93)33 (-109 to 174)
SecondaryChange From Baseline to Week 192 in CD4 Count
Time frame:
Baseline to 192 weeks
Reported as:
Median · cells/mm^3
Change From Baseline to Week 192 in CD4 Count
cells/mm^3Tenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 192 in CD4 Count166 (-82 to 333)-70 (-155 to 220)-23 (-46 to 1)
SecondaryChange From Baseline to Week 240 in CD4 Count
Time frame:
Baseline to 240 weeks
Reported as:
Median · cells/mm^3
Change From Baseline to Week 240 in CD4 Count
cells/mm^3Tenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 240 in CD4 Count221 (59 to 368)571 (-13 to 1155)258 (258 to 258)
SecondaryChange From Baseline to Week 288 in CD4 Count
Time frame:
Baseline to 288 weeks
Reported as:
Median · cells/mm^3
Change From Baseline to Week 288 in CD4 Count
cells/mm^3Tenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 288 in CD4 Count310 (310 to 310)100 (100 to 100)309 (309 to 309)
SecondaryChange From Baseline to Week 336 in CD4 Count

No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

Time frame:
Baseline to 336 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 24 in CD4 Percentage

CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

Time frame:
Baseline to 24 weeks
Reported as:
Median · Percentage of CD4 lymphocytes
Change From Baseline to Week 24 in CD4 Percentage
Percentage of CD4 lymphocytesTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 24 in CD4 Percentage3.0 (0.0 to 6.0)2.0 (-1.0 to 4.0)0.0 (-3.0 to 3.0)-1.0 (-3.0 to 2.0)
Statistical analysis
  • Tenofovir DF vs Placebo · Van Elteren test · p = 0.26 (No adjustments for multiple comparisons were made.)P-value is from a Van Elteren test stratified by baseline GSS (without tenofovir DF) \<= or \> median (median GSS is 2).
SecondaryChange From Baseline to Week 48 in CD4 Percentage

CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

Time frame:
Baseline to 48 weeks
Reported as:
Median · Percentage of CD4 lymphocytes
Change From Baseline to Week 48 in CD4 Percentage
Percentage of CD4 lymphocytesTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 48 in CD4 Percentage6.0 (2.5 to 9.0)5.0 (2.0 to 8.0)2.0 (1.0 to 4.0)-1.0 (-4.0 to 7.0)
Statistical analysis
  • Tenofovir DF vs Placebo · Van Elteren test · p = 0.63 (No adjustments for multiple comparisons were made.)P-value is from a Van Elteren test stratified by baseline GSS (without tenofovir DF) \<= or \> median (median GSS is 2).
SecondaryChange From Baseline to Week 96 in CD4 Percentage

CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

Time frame:
Baseline to 96 weeks
Reported as:
Median · Percentage of CD4 lymphocytes
Change From Baseline to Week 96 in CD4 Percentage
Percentage of CD4 lymphocytesTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 96 in CD4 Percentage5.0 (2.0 to 8.0)2.0 (0.0 to 5.0)9.0 (2.0 to 15.0)
SecondaryChange From Baseline to Week 144 in CD4 Percentage

CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

Time frame:
Baseline to 144 weeks
Reported as:
Median · Percentage of CD4 lymphocytes
Change From Baseline to Week 144 in CD4 Percentage
Percentage of CD4 lymphocytesTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 144 in CD4 Percentage6.5 (-2.0 to 13.0)0.0 (-4.0 to 8.0)5.5 (2.0 to 9.0)
SecondaryChange From Baseline to Week 192 in CD4 Percentage

CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

Time frame:
Baseline to 192 weeks
Reported as:
Median · Percentage of CD4 lymphocytes
Change From Baseline to Week 192 in CD4 Percentage
Percentage of CD4 lymphocytesTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 192 in CD4 Percentage5.0 (-2.0 to 11.6)1.9 (-1.0 to 10.0)4.8 (1.5 to 8.0)
SecondaryChange From Baseline to Week 240 in CD4 Percentage

CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

Time frame:
Baseline to 240 weeks
Reported as:
Median · Percentage of CD4 lymphocytes
Change From Baseline to Week 240 in CD4 Percentage
Percentage of CD4 lymphocytesTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 240 in CD4 Percentage10.0 (-2.0 to 13.3)8.9 (8.2 to 9.6)18.9 (18.9 to 18.9)
SecondaryChange From Baseline to Week 288 in CD4 Percentage

CD4 percentage is the percentage of total lymphocytes that are CD4 cells.

Time frame:
Baseline to 288 weeks
Reported as:
Median · Percentage of CD4 lymphocytes
Change From Baseline to Week 288 in CD4 Percentage
Percentage of CD4 lymphocytesTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Change From Baseline to Week 288 in CD4 Percentage7.4 (7.4 to 7.4)4.0 (4.0 to 4.0)11.9 (11.9 to 11.9)
SecondaryChange From Baseline to Week 336 in CD4 Percentage

No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

Time frame:
Baseline to 336 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 24
Time frame:
Baseline to 24 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 24
Percentage of participantsTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 2456.851.2012.5
Statistical analysis
  • Tenofovir DF vs Placebo · Fisher Exact · p = 0.67 (No adjustments for multiple comparisons were made.)No adjustments were made.
SecondaryPercentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 48
Time frame:
Baseline to 48 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 48
Percentage of participantsTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 4847.753.700
Statistical analysis
  • Tenofovir DF vs Placebo · Fisher Exact · p = 0.67 (No adjustments for multiple comparisons were made.)No adjustments were made.
SecondaryPercentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 96
Time frame:
Baseline to 96 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 96
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 9673.75.933.3
SecondaryPercentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 144
Time frame:
Baseline to 144 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 144
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 14490.000
SecondaryPercentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 192
Time frame:
Baseline to 192 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 192
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 19271.4050.0
SecondaryPercentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 240
Time frame:
Baseline to 240 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 240
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 240100.00100.0
SecondaryPercentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0log 10 Copies/mL From Baseline to Week 288
Time frame:
Baseline to 288 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0log 10 Copies/mL From Baseline to Week 288
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0log 10 Copies/mL From Baseline to Week 288100.000
SecondaryPercentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 336

No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

Time frame:
Baseline to 336 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 24
Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 24
Percentage of participantsTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 2440.941.583.36.3
Statistical analysis
  • Tenofovir DF vs Placebo · Fisher Exact · p = 1.00 (No adjustments for multiple comparisons were made.)No adjustments were made.
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
Percentage of participantsTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 4834.143.977.80
Statistical analysis
  • Tenofovir DF vs Placebo · Fisher Exact · p = 0.38 (No adjustments for multiple comparisons were made.)No adjustments were made.
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 9663.270.633.3
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144
Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA >= 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 14470.072.70
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 192
Time frame:
Week 192
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 192
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 19257.180.050.0
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 240
Time frame:
Week 240
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 240
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 24075.0100.0100.0
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 288
Time frame:
Week 288
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 288
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 2880100.00
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 336

No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

Time frame:
Week 336

No measurements were reported for this outcome.

SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
Percentage of participantsTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 2420.534.177.80
Statistical analysis
  • Tenofovir DF vs Placebo · Fisher Exact · p = 0.22 (No adjustments for multiple comparisons were made.)No adjustments were made.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
Percentage of participantsTenofovir DFPlaceboPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 4827.336.661.10
Statistical analysis
  • Tenofovir DF vs Placebo · Fisher Exact · p = 0.48 (No adjustments for multiple comparisons were made.)No adjustments were made.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 9647.458.833.3
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144
Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 14470.045.50
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 192
Time frame:
Week 192
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 192
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 19242.960.050.0
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 240
Time frame:
Week 240
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 240
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24075.0100.0100.0
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 288
Time frame:
Week 288
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 288
Percentage of participantsTenofovir DFPlacebo/TDF, HIV-1 RNA < 1000 Copies/mLPlacebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 2880100.00
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 336

No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.

Time frame:
Week 336

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Virologic Failure Through Week 48

Virologic failure was defined as either nonresponse or viral rebound. * Nonresponse (failure to achieve response). Response was defined as either * A ≥ 0.5 log10 copies/mL decrease in HIV-1 RNA from baseline at 2 consecutive visits, or * HIV-1 RNA \< 400 copies/mL at 2 consecutive visits. * Viral rebound was defined as either * Participants who achieved a ≥ 0.5 log10 copies/mL decrease from baseline in plasma HIV-1 RNA at 2 consecutive visits, who then subsequently achieved plasma HIV-1 RNA values ≥ 1.0 log10 copies/mL above their on-study nadir (lowest value) and/or plasma HIV-1 RNA values ≥ the baseline value at 2 consecutive visits, or * Participants who achieved plasma HIV-1 RNA levels of \< 400 copies/mL at 2 consecutive visits, and then subsequently had plasma HIV-1 RNA levels \> 1000 copies/mL at 2 consecutive visits. The virologic failure rate was estimated from Kaplan-Meier product limit method by including all HIV-1 RNA data collected during the double-blind phase.

Time frame:
Up to 48 weeks
Reported as:
Number · Kaplan-Meier percentage
Percentage of Participants With Virologic Failure Through Week 48
Kaplan-Meier percentageTenofovir DFPlacebo
Percentage of Participants With Virologic Failure Through Week 485139
Statistical analysis
  • Tenofovir DF vs Placebo · Log Rank · p = 0.29 (No adjustments for multiple comparisons were made.)No adjustments were made.

Adverse events

Collected over Up to Week 294 plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenofovir DF—10/45 (22.2%)44/45 (97.8%)
Placebo—3/42 (7.1%)35/42 (83.3%)
All TDF—20/81 (24.7%)76/81 (93.8%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventTenofovir DFPlaceboAll TDF
PneumoniaInfections and infestations3/451/425/81
SinusitisInfections and infestations2/450/422/81
Pneumocystis Jiroveci PneumoniaInfections and infestations2/450/422/81
Herpes ZosterInfections and infestations0/450/423/81
CellulitisInfections and infestations0/451/420/81
Cerebral ToxoplasmosisInfections and infestations0/451/420/81
MastoiditisInfections and infestations0/451/420/81
CryptococcosisInfections and infestations1/450/421/81
GastroenteritisInfections and infestations1/450/421/81
Respiratory Tract InfectionInfections and infestations1/450/421/81
Most frequent other events
Showing 10 of 36
Most frequent other events
EventTenofovir DFPlaceboAll TDF
VomitingGastrointestinal disorders16/455/4221/81
SinusitisInfections and infestations12/456/4224/81
CoughRespiratory, thoracic and mediastinal disorders11/456/4224/81
NauseaGastrointestinal disorders11/453/4215/81
DiarrhoeaGastrointestinal disorders10/454/4217/81
NasopharyngitisInfections and infestations8/457/4218/81
Upper Respiratory Tract InfectionInfections and infestations8/453/4217/81
HeadacheNervous system disorders6/455/4216/81
Abdominal PainGastrointestinal disorders8/455/429/81
DizzinessNervous system disorders8/455/4211/81

Baseline characteristics

Safety Analysis Set: participants were randomized and received at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)Tenofovir DFPlaceboTotal
<=18 years454287
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Tenofovir DFPlaceboTotal
Mean14 ± 1.514 ± 1.514 ± 1.5
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir DFPlaceboTotal
Female242549
Male211738
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tenofovir DFPlaceboTotal
Hispanic or Latino454287
Not Hispanic or Latino000
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tenofovir DFPlaceboTotal
White232245
Black or African Heritage141125
Mulatto448
Mixed Race123
Indian Descendant112
Mestizo022
Black and White Race101
South American Indian101
Region of Enrollment
Region of Enrollment(participants)Tenofovir DFPlaceboTotal
Panama224
Brazil434083
Body Mass Index
Body Mass Index(kg/m^2)Tenofovir DFPlaceboTotal
Mean18.72 ± 2.30419.99 ± 3.23819.33 ± 2.849
CD4 Cell Count
CD4 Cell Count(cells/mm^3)Tenofovir DFPlaceboTotal
Mean390 ± 244.0357 ± 200.8374 ± 223.5

4 further baseline measures are reported on the registry.

08

Study locations

18 sites
  • Faculdade de Medicina - UFMG
    Belo Horizonte - MG, Brazil
  • Santa Casa de Belo Horizonte
    Belo Horizonte - MG, Brazil
  • Hospital e Maternidade Celso Pierro
    Campinas - SP, Brazil
  • Universidade Estadual de Campinas - UNICAMP
    Campinas - SP, Brazil
  • Centro de Doenças Infecciosas e Parasitárias
    Campo Grande - MS, Brazil
  • Hospital das Clinicas da Universidade Federal do Parana - UFPR
    Curitiba - PR, Brazil
  • Hospital Infantil Joana de Gusmão
    Florianópolis - SC, Brazil
  • Hospital Municipal Sao Jose
    Joinville - SC, Brazil
  • Hospital Materno Infantil Professor Fernando Figueira- IMIP
    Recife, Brazil
  • Hospital dos Servidores do Estado
    Rio de Janeiro, Brazil
  • Hospital Geral de Nova Iguacu Ambulatorio de DST e AIDS
    Rio de Jeneiro, Brazil
  • Hospital Guilherme Alvaro
    Santos, Brazil
  • Instituto da Crianca do Hospital das Clinicas da FMUSP Depto de Pediatria
    Sao Paulo - SP, Brazil
  • Instituto de Infectologia Emilio Ribas
    Sao Paulo - SP, Brazil
  • NEIMPE - Dept of Pediatrics Hospital das Clinicas FMRP-USP
    Sao Paulo, Brazil
  • Universidade Federal de Sao Paulo
    Vila Clementino, Brazil
  • Hospital Infantil Nossa Senhora da Gloria Servico de Infectologia Pediatria
    Vitoria - ES, Brazil
  • Hospital del Nino
    Panama City, Panama
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Sep 2008 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2006
First posted
Jul 14, 2006
Start
Jun 2006
Primary completionActual
Sep 2008
CompletionActual
Dec 2013
Results first posted
Aug 19, 2010
Last update
Jul 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00352053
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 14, 2006
Start date
Jun 2006
Primary completion
Sep 2008
Completion
Dec 2013
Results posted
Aug 19, 2010
Last update
Jul 14, 2015

Study contacts

Erin Quirk, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion